Study shows linkage between weight loss amount and degree of benefit
Phase I study also reveals possible resistance mechanisms to HER2 antibodies
Sustained success requires a cultural shift
Radiogenomic signature could identify patients likely to benefit from targeted therapy
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Doctors called to heal, not just treat
Phase 1b trial shows good response rate
A breast oncologist’s answer
Safe, effective, welcome option
Neratinib and trastuzumab emtansine (T-DM1) combination potent and well tolerated
Clinical trials testing olaparib in breast cancer